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Abstract
There is controversy regarding the nature and degree of intellectual and memory deficits in chronic Lyme disease. In
this study, 81 participants with rigorously diagnosed chronic Lyme disease were administered the newest revisions
of the Wechsler Adult Intelligence Scale (WAIS-III) and Wechsler Memory Scale (WMS-III), and compared to 39
nonpatients. On the WAIS-III, Lyme disease participants had poorer Full Scale and Performance IQ’s. At the subtest
level, differences were restricted to Information and the Processing Speed subtests. On the WMS-III, Lyme disease
participants performed more poorly on Auditory Immediate, Immediate, Auditory Delayed, Auditory Recognition
Delayed, and General Memory indices. Among WMS-III subtests, however, differences were restricted to Logical
Memory (immediate and delayed) and Family Pictures (delayed only), a Visual Memory subtest. Discriminant
analyses suggest deficits in chronic Lyme are best characterized as a combination of memory difficulty and
diminished processing speed. Deficits were modest, between one-third and two-thirds of a standard deviation,
consistent with earlier studies. Depression severity had a weak relationship to processing speed, but little other
association to test performance. Deficits in chronic Lyme disease are consistent with a subtle neuropathological
process affecting multiple performance tasks, although further work is needed to definitively rule out nonspecific
illness effects. (JINS, 2006, 12, 119–129.)
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INTRODUCTION
Lyme disease is caused by infection with the tick-borne
spirochete Borrelia burgdorferi. It typically starts with an
erythematous rash that evolves within days to weeks into a
multisystemic illness affecting one or more bodily systems,
including joints, heart, eyes, peripheral and0or central ner-
vous systems (Steere, 2001). The most common clinical
profile includes arthralgias, myalgias, paresthesias, radicu-
lar pain, headaches, marked fatigue, and a subjective sense
of clouded thinking. Neuropsychological testing of these
patients reveals problems with attention, memory, verbal
fluency, and concentration that are commonly attributed to
an encephalopathy (Krupp et al., 1991). Psychiatric mani-
festations can occur as well, and are most often expressed
as irritability, depression, and anxiety, and much less fre-
quently as psychosis or dementia (Fallon & Nields, 1994).
Patients generally do well when treated rapidly after the
initial infection, but not all cases are quickly diagnosed,
resulting in a more disseminated infection with variable
responses to standard courses of antibiotic therapy. When
Lyme disease has central neurologic manifestations, for
example, up to 40% of patients will have a limited response
to treatment or relapse months to years after discontinua-
tion of antibiotic therapy (Logigian et al., 1990).
If symptoms persist after a standard course of antibiotic
therapy, patients are considered to have “chronic Lyme dis-
ease” or “post-treatment Lyme disease” (Fallon et al. 1998).
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There is substantial controversy about this chronic phase of
Lyme disease, in terms of clinical phenomenology, validity
of laboratory testing, and treatment. Symptomatology is vari-
able, both in type and severity. Persistent symptoms may
reflect either persistent infection or past infection with resid-
ual immunologic reactivity or structural damage. It is rarely
possible to culture the organism once disseminated beyond
the rash phase, and laboratory test results with the enzyme-
linked immunosorbent assay (ELISA) or Western blot are
at best only an indirect marker of infection.
The most frequent finding from neuropsychological
studies of chronic Lyme disease is impaired memory, espe-
cially on verbal list-learning tasks (Krupp et al., 1991; Kap-
lan et al., 1992; Shadick et al., 1994; Benke et al., 1995;
Bujak et al., 1996; Ravdin et al., 1996; Gaudino et al., 1997;
Kaplan et al., 1999; Pollina et al., 1999b;). Verbal fluency is
often impaired relative to control groups (Krupp et al., 1991;
Benke et al., 1995; Gaudino et al., 1997), although fluency
deficits are not found in all samples (Kaplan et al., 1999;
Svetina et al., 1999; Kaplan et al., 2003). Impaired “initia-
tion speed” has been found by one group (Pollina et al.,
1999a), but, again, not replicated across all studies. The
largest, most recent study of patients with chronic Lyme
disease (Kaplan et al., 2003) found poorest performance in
the areas of processing speed (Symbol-Digit Modalities Test)
and delayed memory recall (Rey Auditory Verbal Learning
Tests). However, standardized group means were only
approximately 0.5 SD below the level of population norms,
and no nonpatient comparison group was studied.
A review of previous neuropsychological studies of
chronic Lyme disease (Westervelt & McCaffrey, 2002) con-
cluded that these deficits likely reflect some type of “fron-
tal system dysfunction.” However, brain imaging studies of
patients with chronic Lyme disease typically find nonspe-
cific heterogeneous reductions in blood flow or metabolism
spread throughout the cortex and subcortical white matter,
and no consistent focal deficits in frontal lobes (Logigian
et al., 1997; Newberg et al., 2002). Our own previous study
of cerebral blood flow in chronic Lyme disease using an
older Xenon-inhalation, external-detector technology found
deficits in compartment-modeled white matter flow in tem-
poral and parietal regions (Fallon et al., 2003). These defi-
cits correlated with poorer verbal memory performance and
relative deficits in WAIS-R Block Design and Digit Sym-
bol test performance.
The lack of focal imaging findings and the mild nature of
neuropsychological deficits found in chronic Lyme disease
patients have lead some to attribute their deficits to psychi-
atric disturbance. Depression and other psychopathology
ratings are often elevated in chronic Lyme patients. These
ratings, however, typically do not correlate with neuropsy-
chological performance (Kaplan et al., 1992; Barr et al.,
1999). Fatigue severity, on the other hand, often does (Rav-
din et al., 1996; Gaudino et al., 1997).
Studies of larger samples of patients with well-
characterized chronic Lyme disease, using standard assess-
ment instruments, are needed to clarify inconsistencies
regarding level of impairment in these patients. The study
we report here examined a large sample of participants with
carefully diagnosed chronic Lyme disease using the third
revisions of the Wechsler Adult Intelligence Scale (WAIS-III)
and Wechsler Memory Scale (WMS-III). Its purpose was to
characterize these participants’general intellectual and mem-
ory function and to determine if there is a typical profile of
impairment on these extensively normed and commonly
used tests.
This is the first study of chronic Lyme disease to use the
newest revisions of the WAIS and WMS. In general, indi-
ces and subtests from the earlier versions of these scales did
not discriminate well between chronic Lyme disease patients
and other groups. Five previous studies used various sub-
tests of the WAIS-R, and none used the entire WAIS-R.
Gaudino et al. (1997) found differences between chronic
Lyme disease on WAIS-R Digit Span, but were the only
group to report a difference on any subtest (Krupp et al.,
1991; Benke et al., 1995; Gaudino et al., 1997; Kaplan
et al., 1999). Five studies used WMS-R tasks. Bujak et al.
(1996) administered the entire scale, but only found differ-
ences on the Attention0Concentration index, and none of
the primary memory scales. Krupp et al. (1991) found dif-
ferences between chronic Lyme disease and controls on
Logical Memory and Paired Associates, but other studies
found no differences with nonpatient controls in either Log-
ical Memory (Kaplan et al., 1992; Gaudino et al., 1997) or
Paired Associates (Kaplan et al., 1992; Shadick et al., 1994).
Kaplan et al. (1992) found differences in Visual Reproduc-
tion, but Shadick et al. (1994) did not.
This is not only the first study to report WAIS-III and
WMS-III scores in chronic Lyme disease, but also the first
to use all subtests necessary to compute the full comple-
ment of index scores for each test, as well as demographi-
cally adjusted T-scores for all index and subtest scores.
T-score adjustments correct for the influence of demo-
graphic factors such as sex, ethnicity, and, most important,
education level, over and above the usual correction for age
provided by the Wechsler scales’ standard scores. These
adjustments are useful because many Lyme endemic areas
are suburbs where educational attainment, occupational sta-
tus, and premorbid ability levels are high (Orloski et al.,
2000). Consequently, participants may decline a standard
deviation or more from premorbid levels but still perform
in an average range for the population.
METHODS
Research Participants
Participants included 81 patients with chronic Lyme dis-
ease and 39 nonpatient comparison participants. Patients
met the following inclusion criteria: (a) documentation of
Lyme disease using the CDC surveillance criteria (1997)
for clinical features and laboratory tests, (b) a currently
reactive IgG Western blot by CDC criteria (as assessed by
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University Hospital of Stony Brook), (c) prior treatment for
Lyme disease with at least 3 weeks of either IV ceftriaxone
or cefotaxime, and (d) cognitive problems that started after
getting Lyme disease and that have persisted or returned
despite prior treatment. Exclusion criteria included: (a) the
presence of comorbid diseases that could cause significant
cognitive problems (i.e., major neurological illnesses
unrelated to Lyme, or psychiatric illnesses predating the
onset of Lyme), (b) history of head trauma, hypoxia, or loss
of consciousness, (c) history of a pre-Lyme disease cogni-
tive disorder, such as a learning disability. Nonpatient com-
parison participants had no history of Lyme disease or a
Lyme-like illness, had currently negative Western blot assays
for Lyme disease, and had no history of neurologic or psy-
chiatric disorders.
Instruments
Participants received a self-report symptom questionnaire
(see Table 1 for symptoms surveyed), the Beck Depression
Inventory (BDI), and the third revisions of the Wechsler
Adult Intelligence Scale (WAIS-III) and Wechsler Memory
Scale (WMS-III). The WAIS-III included all subtests nec-
essary to compute all IQ scores and all index scores; the
WMS-III included all subtests necessary to compute all index
scores. Tests were administered by trained technicians under
the supervision of the first author. Scaled subtest scores and
standard index and IQ scores were computed for each scale
and reported in tables. However, all statistical analyses were
computed on demographically adjusted T-scores, obtained
from algorithms developed by Robert Heaton and his col-
leagues at the University of California, San Diego and now
incorporated into the scoring software (WAIS-III0WMS-III
Scoring Assistant) available from the tests’ publisher (Psy-
chological Corporation).
Participants also received two IQ estimation instru-
ments, the Barona demographic formula (including age, sex,
ethnicity, education, occupational attainment, and region of
residence; Barona et al., 1984) and the North American
Adult Reading Test (NAART; Blair & Spreen, 1989). The
two were also combined in a regression equation in an
attempt to improve the prediction of IQs in our nonpatient
Table 1. Participant characteristics
Lyme Patients Nonpatients p valuea
Demographics
N 81 39
Age 47.9 (11.0) 43.9 (10.6) .059
Sex 54.3% F 53.8% F .961
Education, years 14.7 (2.6) 15.4 (2.6) .179
Estimated IQs
Barona 111.8 (6.4) 112.0 (5.9) .863
NAART 109.2 (8.9) 110.9 (9.4) .329
Combined regression estimate 115.6 (9.2) 117.4 (9.7) .330
Depression rating
BDI 15.0 (8.3) 3.1 (6.2) ,.001*
Symptoms (patients only)













Illness & treatment history
Time from onset to first treatment (months) 22.6 (39.8) [median5 8]
Length of illness (months) 105.2 (79.4) [median5 84]
Length of treatment with IV antibiotics (months) 2.3 (2.6) [median5 1.3]
Length of treatment with oral antibiotics (months) 6.2 (7.0) [median5 2.8]
at test for continuous variables, chi-squared for categorical variables; p values reflect comparison of T-scores, except where T-scores
are not available.
*p , .05.
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participants (to improve accuracy and manage anticipated
ceiling effects on these scales; highest IQ attainable on the
Barona is 121, on the NAART it is 128; see Willshire et al.,
1991). After deriving an equation to optimize prediction of
WAIS-III IQ in our nonpatient sample:
127.91 .0573 Barona IQ Estimate2 .781
3NAART Error Score,
this equation was then applied in our patient sample.
Procedures
All participants were potential participants in a treatment
study of chronic Lyme disease involving 10 weeks of intra-
venous antibiotic or placebo (or no treatment for a group of
serially assessed nonpatients), serial PET and MRI scans,
medical examinations, and neuropsychological evalua-
tions. Testing reported here was an initial screening to deter-
mine level of impairment for inclusion0exclusion in the
treatment component. Participants were recruited via adver-
tisement and physician referral. Nonpatients were recruited
from areas demographically similar to patients. All partici-
pants were initially screened by telephone, then received a
blood test (to determine current serological status) and a
face-to-face evaluation. Documentation of past illness and
treatment was gathered from past physicians by study staff.
Patient participants in this study account for 5.6% (810
1458) of those who received telephone screening, and 55.5%
(810146) of those who were currently IgG Western Blot
positive. Excluded participants with IgG positive serology
most often did not have sufficient documentation of past
illness or treatment for inclusion in the neuropsychological
screening. This study was approved by the local Institu-
tional Review Board. All participants signed informed con-
sent for this phase of the study.
Statistical Analyses
Demographic variables and depression ratings for Lyme
and nonpatient groups were compared using t tests at an
alpha level of .05. Demographically-corrected T-scores for
WAIS-III and WMS-III IQ’s, indices, and subtests were
compared via t test at an alpha level of .01, to control for
number of comparisons. A more conservative adjustment
for multiple comparison (e.g., Bonferroni correction) was
not appropriate because WAIS-III and WMS-III scores are
heavily intercorrelated.1
Stepwise discriminant function analysis was then run using
those tests that discriminated between the two groups, in
order to determine the degree of overlap among these test
differences. Discriminant analyses were run two ways: first,
using WAIS-III and WMS-III index scores that differed
between groups, and, second, using WAIS-III and WMS-III
subtest scores that differed between groups.
Finally, depression ratings and self-reported symptom0
clinical history variables were compared to test scores using
Spearman correlations (duration of illness and treatment
variables were highly skewed) and t tests. Due to the explor-
atory nature of these analyses, associations0group differ-




Chronic Lyme participants and nonpatients were compara-
ble in age, sex ratio, and education level (Table 1.). Although
the difference in age approached significance, age effects
on neuropsychological performance were controlled in nor-
mative adjustments of test scores and are not likely to affect
group differences. Chronic Lyme disease participants and
nonpatients were comparable, as well, in estimated IQ,
whether assessed via the Barona demographic scale, the
NAART, or our regression formula combining the two mea-
sures. These samples were well above average in expected
intelligence level. IQ estimates generated by the Barona
and NAART fell below the level of actual IQs obtained by
the nonpatient comparison group (due to anticipated ceiling
effects; see actual IQs in Table 2); regression combination
of the two estimates, however, accurately predicted WAIS-III
IQ in nonpatients (r 5 .73; estimates correlated best with
WAIS-III Verbal Comprehension, r 5 .79, and Working
Memory, r5 .65, indices, and with Immediate Memory, r5
.54, and General Memory, r5 .59, all p , .001).
Compared to nonpatients, BDI scores were significantly
higher in the Lyme patient group, such that their mean score
fell within the mildly depressed range.
Symptomatology, Illness History,
and Treatment History
The majority of the patient participants reported a combi-
nation of rheumatologic, neurologic, and psychiatric0
psychological symptoms. The most common rheumatologic
symptoms were joint and muscle pain (arthralgias, myal-
gias). The most common neurologic symptom was head-
ache (other than complaint of cognitive problems, which
was required for study entry). Median duration of illness in
this sample was 7 years, and median time before initiation
of treatment was 8 months. Participants had received a
median of nearly 3 months of oral antibiotics and 5 weeks
of IV antibiotic treatment. Overall, this is a symptomatic
sample of individuals with chronic illness who had received
multiple courses of treatment, with recurrence of symptoms.
1 Based on a Monte Carlo simulation using WMS-III correlational
structure (and confirmed with WMS-III normative data), family-wise error
rate across index scores is approximately .02 at a nominal alpha level of
.05. WAIS-III has a similar correlational structure; therefore this alpha
level was halved for comparisons across both scales.
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WAIS-III and WMS-III Index Scores
WAIS-III and WMS-III index scores are presented in Table 2,
and index score profiles are illustrated in Figure 1. Lyme
patients performed more poorly in general than nonpatients.
Statistical differences at the .01 level were found in WAIS-III
Full Scale and Performance IQ, but the only index score to
differentiate the groups at p , .01 was Processing Speed.
Verbal Comprehension differences fell at the p5 .01 crite-
rion for significance, even though estimated premorbid IQs
were similar.
Table 2. WAIS-III and WMS-III standard and T-scores
Standard scores Adjusted T-scores Comparison
Lyme patients Nonpatients Lyme patients Nonpatients p valuea
WAIS-III
Full Scale IQ 108.3 (13.4) 117.4 (13.7) 50.9 (10.0) 57.1 (10.0) .003*
Verbal IQ 108.6 (14.0) 116.1 (15.0) 51.5 (10.0) 56.5 (10.8) .017
Performance IQ 105.1 (12.8) 114.3 (12.8) 50.0 (10.2) 56.0 (9.2) .003*
Indices
Verbal Comprehension 109.4 (15.3) 117.9 (13.6) 52.2 (11.4) 58.0 (9.8) .010**
Perceptual Organization 108.5 (14.1) 115.5 (14.0) 51.9 (10.7) 56.3 (10.6) .043
Working Memory 102.8 (13.3) 108.3 (15.8) 47.5 (9.1) 50.8 (11.4) .099
Processing Speed 100.6 (12.5) 109.9 (12.7) 46.1 (9.5) 53.1 (9.4) ,.001*
Subtests
Picture Completion 11.5 (2.9) 12.6 (2.7) 51.9 (10.9) 55.6 (9.9) .084
Vocabulary 12.1 (3.1) 13.6 (2.7) 53.3 (11.2) 57.9 (9.4) .035
Digit Symbol 10.0 (2.5) 11.8 (3.0) 46.0 (9.5) 52.8 (11.4) .001*
Similarities 11.8 (3.0) 12.6 (2.8) 51.8 (10.9) 54.9 (10.0) .323
Block Design 10.6 (2.9) 12.0 (2.8) 48.2 (10.7) 52.9 (10.1) .030
Arithmetic 10.8 (2.6) 11.0 (3.0) 48.5 (8.5) 48.4 (11.0) .954
Matrix Reasoning 12.2 (2.8) 12.9 (2.3) 54.0 (10.0) 55.7 (9.0) .394
Digit Span 10.3 (2.7) 11.5 (3.3) 47.7 (9.4) 51.4 (10.9) .068
Information 11.1 (2.6) 13.3 (2.3) 49.6 (9.9) 57.4 (9.0) ,.001*
Picture Arrangement 10.6 (2.6) 11.8 (3.1) 48.4 (9.1) 52.1 (10.5) .065
Comprehension 12.6 (2.8) 13.4 (2.8) 55.8 (9.8) 58.1 (10.1) .274
Symbol Search 10.3 (2.4) 11.8 (2.4) 47.2 (9.0) 52.0 (8.7) .009*
Letter Number Sequencing 10.5 (3.1) 11.8 (2.5) 47.9 (10.6) 52.2 (8.9) .038
WMS-III
Indices
Auditory Immediate 100.4 (14.8) 111.0 (14.8) 46.1 (9.9) 53.1 (9.6) ,.001*
Visual Immediate 100.7 (15.6) 103.5 (14.1) 48.3 (10.8) 50.2 (9.4) .364
Immediate Memory 100.6 (16.0) 109.0 (15.2) 46.7 (10.9) 52.4 (9.9) .007*
Auditory Delayed Memory 101.8 (14.0) 112.5 (12.9) 47.1 (9.5) 54.2 (8.3) ,.001*
Visual Delayed Memory 100.6 (14.2) 105.0 (14.1) 47.7 (9.8) 50.6 (9.2) .126
Auditory Recognition Delay 102.0 (13.2) 111.4 (16.8) 47.8 (8.9) 54.3 (11.4) .001*
General Memory 101.7 (14.3) 111.7 (14.9) 47.1 (9.8) 53.9 (9.7) ,.001*
Working Memory 104.2 (15.6) 110.5 (15.1) 49.1 (11.1) 53.3 (10.8) .056
Subtests
Logical Memory I 9.4 (2.5) 12.5 (2.8) 43.2 (8.3) 53.9 (9.0) ,.001*
Faces I 10.9 (3.2) 10.6 (2.9) 52.0 (11.0) 50.8 (9.4) .545
Paired Associates I 10.8 (3.2) 11.3 (2.7) 49.7 (10.6) 51.0 (8.7) .494
Family Pictures I 9.4 (2.7) 10.6 (2.8) 45.0 (9.0) 49.1 (9.3) .023
Spatial Span 11.0 (2.8) 11.5 (2.8) 50.7 (9.6) 52.4 (9.6) .381
Letter Number Sequencing 10.4 (3.1) 12.0 (2.7) 47.2 (11.0) 52.4 (9.6) .013
Logical Memory II 10.0 (2.9) 13.0 (2.7) 45.6 (9.6) 55.8 (8.4) ,.001*
Faces II 11.1 (2.4) 10.5 (2.8) 52.2 (8.4) 49.7 (9.1) .138
Paired Associates II 10.7 (2.7) 11.3 (2.1) 49.3 (9.1) 50.8 (7.2) .357
Family Pictures II 9.1 (3.0) 11.1 (2.8) 43.9 (10.1) 50.7 (9.2) .001*
Auditory Recognition Delay 10.4 (2.6) 12.3 (3.4) 47.8 (8.9) 54.3 (11.4) .001*
at test for continuous variables; p values reflect comparison of T-scores, except where T-scores are not available.
*p , .01.
**p5 .01.
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On the WMS-III, group differences were found in Audi-
tory Immediate, Auditory Delayed, Auditory Recognition
Delayed, and General Memory indices. T-scores on these
measures fell an average of about 7 points below non-
patients (;203 of a standard deviation), and 3 points below
the external population norm of 50 (;103 of a standard
deviation). Chronic Lyme patients’ WMS-III scores gener-
ally fell below the level of their regression estimated IQ
and WAIS-III Verbal Comprehension index. However, this
was also true for the nonpatient comparison group.
WAIS-III Subtest Scores
Lyme patients performed significantly more poorly on both
Processing Speed subtests, Digit Symbol and Symbol Search,
and on the Information subtest (Table 2 and Figure 2). Sub-
tests are generally consistent with index score results,
although they suggest that patient0nonpatient differences
may have been found on the Working Memory index if
nonpatients’ T-score on the Arithmetic subtest was not rel-
atively low.
WMS-III Subtest Scores
Differences between chronic Lyme and nonpatients on
WMS-III subtests (Table 2 and Figure 3) reveal a pattern
that was not expected on the basis of index score differ-
ences. Although patients differed most consistently on the
auditory memory indices, their poorest subtest perfor-
mances were on Logical Memory (an auditory memory sub-
test) and Family Pictures (a visual memory subtest). No
differences were observed on Paired Associates or Faces
subtests, immediate or delayed (n.b., the Auditory Recog-
nition Delayed “subtest” is the only score included in the
index of the same name).
Discriminant Analyses
Discriminant analyses revealed that Lyme patients could be
classified on the basis of a function including only the
WMS-III Auditory Delayed index (standardized function
coefficient 5 .671) and WAIS-III Processing Speed (stan-
dardized function coefficient 5 .535). This function cor-
rectly classified 68.8% of all cases (67.1% of Lyme patients,
72.2% of nonpatients).
Using subtest scores, the discriminant function included
only the WMS-III Logical Memory, Immediate subtest.
Using a cutoff of T 5 47, 74.1% of participants could be
correctly classified (73.7% of Lyme, 75.0% of nonpatients).
This cutoff is relatively close to the general population mean
and less than a full standard deviation (;.7 SD) below the
nonpatient comparison group mean, but fell approximately
10 T-score points (one standard deviation) below their own
WAIS-III Vocabulary and Matrix Reasoning scores.
Associations with Other Clinical/Disease
Measures
The Beck Depression Inventory did not correlate with any
WAIS-III or WMS-III index or subtest scores in the Lyme
Fig. 1. Demographically adjusted T-scores for WAIS-III and WMS-III IQ and index scores in chronic Lyme disease
participants and nonpatient comparison participants. Abbreviations: WAIS-III–FSIQ 5 Full Scale IQ, VIQ 5 Verbal
IQ, PIQ5 Performance IQ, Vcomp5Verbal Comprehension, PerOrg5 Perceptual Organization, WkMem5Working
Memory, ProcSp 5 Processing Speed; WMS-III–AudImm 5 Auditory Immediate, VisImm 5 Visual Immediate,
ImmMem 5 Immediate Memory, AudDel 5 Auditory Delayed, VisDel 5 Visual Delayed, AuRecDel 5 Auditory
Recognition Delayed, GenMem5 General Memory, WorkMem5Working Memory.
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patients. BDI correlations with WAIS-III Full Scale IQ (rho5
.06, p5 .66), Verbal IQ (rho5 .03, p5 .85), Performance
IQ (rho5 .06, p5 .64), Verbal Comprehension (rho5 .11,
p 5 .40), Perceptual Organization (rho 5 .15, p 5 .22),
Working Memory (rho 5 2.04, p 5 .73), and Processing
Speed (rho 5 2.12, p 5 .36) indices were all nonsignifi-
cant. Similarly, BDI correlations with WMS-III Auditory
Immediate (rho 5 .18, p 5 .15), Visual Immediate (rho 5
.09, p 5 .46), Immediate Memory (rho 5 .16, p 5 .22),
Auditory Delayed (rho 5 .12, p 5 .34), Visual Delayed
(rho5 .07, p5 .58), Auditory Recognition Delayed (rho5
2.05, p5 .70), General Memory (rho5 .07, p5 .58), and
Working Memory (rho 5 .01, p 5 .94) indices were also
nonsignificant.
Covarying BDI scores in group comparisons made a num-
ber of group differences marginal by our p , .01 signifi-
Fig. 2. Demographically adjusted T scores for WAIS-III subtest scores, grouped by index, in chronic Lyme disease
participants and nonpatient comparison participants. Abbreviations: Voc 5 Vocabulary, Sim 5 Similarities, Inf 5
Information, Pcomp 5 Picture Completion, Bdes 5 Block Design, Matrx 5 Matrix Reasoning, Arith 5 Arithmetic,
Dspan 5 Digit Span, Letnum 5 Letter Number, Dsym 5 Digit Symbol, Symsr 5 Symbol Search, Parr 5 Picture
Arrangement, Comp5 Comprehension.
Fig. 3. Demographically adjusted T-scores for WMS-III IQ subtests in chronic Lyme disease participants and non-
patient comparison participants. Abbreviations: LogMem15 Logical Memory Immediate, Face15 Faces Immediate,
VPA15 Verbal Paired Associates Immediate, FamPic15 Family Pictures Immediate; LogMem25 Logical Memory
Delayed, Face2 5 Faces Delayed, VPA2 5 Verbal Paired Associates Delayed, FamPic2 5 Family Pictures Delayed,
AuRecDel5Auditory Recognition Delayed, Letnum5 Letter Number, SpaSpan5 Spatial Span.
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cance criteria, although most remained significant. Covarying
BDI reduced the significance level of the group comparison
for the Verbal Comprehension index (F[1, 109]5 3.96, p5
.049), but the difference for the Information subtest remained
significant (F[1, 109]5 8.42, p5 .004). Differences for the
Processing Speed index (F[1, 109]5 5.30, p5 .023), Digit
Symbol (F[1, 108] 5 2.62, p 5 .108), and Symbol Search
(F[1, 109]5 3.68, p5 .058) all did not meet the criterion
for significance. On the WMS-III, differences for Auditory
Immediate (F[1, 117] 5 10.84, p 5 .001) and Immediate
Memory (F[1, 117] 5 7.10, p 5 .009), Auditory Delayed
(F[1, 117] 5 8.86, p 5 .004) and General Memory (F[1,
117]5 8.02, p5 .005) remained significant. Auditory Rec-
ognition Delayed (F[1, 117] 5 5.69, p 5 .019) did not.
Differences on Logical Memory Immediate (F[1, 117] 5
28.50, p , .001) and Delayed (F[1, 117] 5 18.19, p ,
.001) and Family Pictures Delayed (F[1, 117]511.38, p5
.001) remained significant. Overall, BDI was a nonsignifi-
cant covariate in all but one of these comparisons [Digit
Symbol: F(1,108) 5 4.58, p 5 .038]. Group differences
related to processing speed appeared to be mildly affected
by covarying BDI, those related to memory were generally
unaffected.
Participants who recalled a tick bite had higher Full Scale
IQ [t(72)5 3.45, p5 .001], Verbal IQ [t(72)5 2.97, p5
.004], Performance IQ [t(72) 5 2.98, p 5 .004], Verbal
Comprehension [t(72) 5 2.62, p 5 .01], Perceptual Orga-
nization [t(72)53.16, p5 .002], Processing Speed [t(72)5
2.42, p5 .02], Auditory Immediate Memory [t(76)5 3.38,
p 5 .001], Immediate Memory [t(76) 5 2.71, p 5 .008],
Auditory Delayed [t(76)5 3.01, p5 .004], Auditory Rec-
ognition Delayed [t(76)52.59, p5 .01], and General Mem-
ory [t(76)53.01, p5 .004] than those who did not. Similarly,
those who reported balance problems had higher Full Scale
[t(72) 5 2.01, p 5 .05] and Verbal IQ [t(72) 5 2.04, p 5
.05], Auditory Immediate [t(77) 5 2.27, p 5 .03], Visual
Immediate [t(77) 5 2.14, p 5 .04], Immediate Memory
[t(77) 5 2.47, p 5 .02], and General Memory [t(77) 5
2.03, p 5 .02]. In each case, there were no differences in
estimated premorbid IQ [t(75)51.40, p5 .17 and t(76)5
.42, p5 .68, respectively] between groups.
Participants complaining of arthritis performed more
poorly on WAIS-III Information [t(74) 5 2.23, p 5 .03],
WMS-III Auditory Recognition Delayed [t(79)5 2.20, p5
.03], General Memory [t(79)51.97, p5 .05], and Logical
Memory Delayed Recall [t(79) 5 2.06, p 5 .04]. Partici-
pants reporting shooting pains, facial palsy, headache, or
sensory hyperacuity did not differ on any performance
measures.
The initial lag in treatment was uncorrelated with any
performance measures; duration of illness was weakly asso-
ciated with poorer Digit Symbol (rho52.26, p5 .04), but
was only one of 41 correlations to reach significance.
Total time receiving IV antibiotics was negatively asso-
ciated with estimated IQ (rho52.23, p5 .05), and nega-
tively associated with Verbal IQ (rho 5 2.27, p 5 .02),
WAIS-III Working Memory (rho52.40, p5 .001), Digit
Span (rho 5 2.33, p 5 .005), Letter Number Sequencing
(rho 5 2.30, p 5 .01), WMS-R General Memory (rho 5
2.26, p 5 .03), WMS-III Working Memory (rho 5 2.32,
p5 .005), and Spatial Span (rho52.25, p5 .03). Associ-
ations remained significant after partialling estimated IQ
(rank) with WAIS-III Working Memory (rho 5 2.34, p 5
.005), Digit Span (rho 5 2.25, p 5 .04), Letter Number
Sequencing (rho52.32, p5 .008), and WMS-III Working
Memory (rho52.24, p5 .04).
Time receiving oral antibiotics, on the other hand, was
positively associated with performance on WMS-R Audi-
tory Immediate Memory (rho 5 .27, p 5 .04), Auditory
Delayed Memory (rho 5 .27, p 5 .04), and Logical Mem-
ory Immediate (rho5 .25, p5 .05) and Delayed (rho5 .29,
p5 .03) subtests.
DISCUSSION
Chronic Lyme disease patients in this study had mild levels
of impairment in processing speed and memory, consistent
with the findings of Kaplan et al. (2003). These impair-
ments are less severe than those found in acute Lyme enceph-
alopathy prior to treatment (Halperin et al., 1990; Gustaw
et al., 2001). These impairments were modest relative to
population norms, although more obvious relative to the
nonpatient comparison group. It is important to note that
Lyme patients’ standard scores on the WAIS-III and
WMS-III are all approximately average, even though Lyme
patients standard score IQ is 7 points below their estimated
premorbid levels. Without demographic adjustment, these
participants would appear to be performing comparably to
the general population. T-scores indicate that they are, in
fact, slightly below average when compared to appropriate
demographic standards, and more clearly deficient relative
to nonpatients of comparable intelligence.
The mild nature of the deficits found here suggests, on
the one hand, that the WAIS-III and WMS-III may not be
ideal for characterizing impairment in chronic Lyme dis-
ease. Their predecessors, the WAIS-R and WMS-R, have a
history of being relatively insensitive, or at least inconsis-
tently sensitive to deficits in chronic Lyme disease (West-
ervelt & McCaffrey, 2002). On the other hand, observed
deficits in processing speed and memory recall for complex
material may have resulted from a diffuse or idiosyncratic
neuropathological process, rather than focal damage to well-
defined cortical areas (Lezak et al., 2004). If this is the
case, it is unlikely that any one test will consistently differ-
entiate Lyme cases across samples. When averaged together,
these patients may be distinguished best by their substan-
dard performance across a variety of tasks. Individual par-
ticipants may show more pronounced impairment in
circumscribed cognitive functions, dependent on the unique
effects of Lyme disease on individual brains. Our own prior
imaging work suggests that chronic Lyme disease affects
white matter (Fallon et al., 2003). Such pathology is more
likely to affect global processing speed and the integration
of cognitive functions rather than any single aspect of cog-
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nitive performance (Rao, 1996; Reed et al., 2004). How-
ever, language functions and recognition memory—affected
in the Lyme sample here—are typically intact in white mat-
ter diseases, unless total lesion load is high (Rao, 1996).
Test scores may also reflect substandard performance due
to nonspecific illness factors such as pain and fatigue. How-
ever, a supplemental analysis of tiredness and somatic con-
cern items from the BDI, either alone or in combination,
revealed no association to test scores.
An interesting discrepancy was found between results of
index score analyses and subtest score analyses on the
WMS-III. Index scores suggest that chronic Lyme patients
were most deficient in Auditory Memory, while subtests
indicate that Lyme patients were only deficient in Logical
Memory from among the auditory tasks, and almost equally
deficient in Family Pictures, a visual memory task. Deficits
in chronic Lyme disease, then, reflect common elements in
these two tasks, such as the inclusion of context and the
need to organize material to be recalled. These tasks may
place greater demands on processing speed to initially encode
material, although, in another supplemental analysis, we
found that covarying WAIS-III Processing Speed Index did
not eliminate group differences on these WMS-III subtests.
Discriminant analyses, similarly, suggest that processing
speed deficits and memory deficits are distinct, in that each
contributes to classification of Lyme cases.
Level of depression was significantly higher in Lyme
patients than nonpatients, with the average BDI score fall-
ing in a “mildly depressed” range. However, as in most
other studies of Lyme encephalopathy, depression severity
did not correlate with test performance. Covariance analy-
ses suggest that depression may account for some degree of
processing speed deficit in Lyme patients, but, overall, BDI
score was a very weak covariate of test performance.
Deficits in processing speed and memory found in Lyme
patients are nonetheless similar to those typically found in
participants with major depression (Veiel, 1997; Zakzanis
et al., 1998), and depression effects cannot be ruled out
completely by correlation and covariance analyses. Although
these deficits presumably have a different etiology in the
two disorders, they may be difficult to distinguish on the
WAIS-III and WMS-III. Deficits on Verbal Comprehension
subtests such as Information and the severity of memory
deficit in Lyme disease are, however, less typical of depres-
sion and suggest a more significant impairment of memory
encoding and retrieval in Lyme disease. Direct comparison
of these groups on the WAIS-III and WMS-III is needed.
The low Information score in Lyme patients could be
interpreted as an indicator of poor premorbid ability, but
this subtest score is low relative to other typical premorbid
ability indicators such as Vocabulary. If the discrepancy
between Information and Vocabulary (difference score) is
entered in the discriminant analysis, it is retained as a sig-
nificant discriminating variable along with Logical Mem-
ory (standardized coefficient .48; for Logical Memory .98;
correct classification: 80.4%). Lyme disease commonly
affects verbal skills such as fluency (Benke et al., 1995;
Gaudino et al., 1997; Krupp et al., 1991) in addition to
memory, and some measures that are typically used as indi-
cators of premorbid ability may be not as reliable in Lyme
patients.
Supplemental analyses of symptom data are difficult to
interpret due to the extensive overlap of symptoms across
participants. Patients who did not observe a tick bite or
have balance problems performed more poorly than those
who did, possibly because the absence of these symptoms
may have obscured recognition of the infection and delayed
diagnosis and treatment. Participants with arthritis, on the
other hand, performed less well on tests that distinguished
patients with chronic Lyme disease from nonpatients. Lag
between initial symptoms and initial treatment, and dura-
tion of illness had surprisingly little relationship to test per-
formance. These participants have received varying courses
of treatment, though, which may have obscured these rela-
tionships. Also surprising was the correlation between lon-
ger treatment with IV antibiotics and poorer working memory
performance. While this correlation could reflect a long-
term adverse effect of IV treatment, it may also mean that
more impaired participants were more likely to receive lon-
ger courses of IV treatment. Length of treatment with oral
antibiotics was, however, positively associated with test per-
formance on key memory measures. More systematic
research on long-term treatment effects is needed before
any firm conclusions can be drawn about these relationships.
There are limitations to this study that may have resulted
in our understating the level of impairment in Lyme disease
participants. As in the study by Kaplan et al. (2003), patients
were recruited based on their interest in participating in a
placebo-controlled treatment trial. These patients may have
milder illness, because physicians would likely recommend
against participation in such a study for patients with marked
encephalopathy and a currently positive IgG Western blot.
In addition, greater than half of the patients in our sample
had more than the standard 3– 4 week course of IV antibi-
otic therapy during earlier treatments. This sample is biased
toward patients who already may have experienced partial
improvement in cognitive symptoms. Another limitation is
that patients had to meet CDC surveillance criteria for Lyme
disease. Because the surveillance criteria do not include
encephalopathy as a criterion, our sample (as well as the
sample of Kaplan et al., 2003) may have systematically
excluded those with Lyme encephalopathy who did not recall
an erythema migrans rash, or develop swollen joints, cra-
nial neuropathy, or meningitis0encephalitis. As noted in
Table 1, all patient participants reported cognitive difficul-
ties, but fully 77.8% also reported arthritis, making this a
multi-symptom sample.
In general, patients with chronic Lyme disease per-
formed more poorly than nonpatients on the WAIS-III and
WMS-III, but there does not appear to be any reasonable
set of cut-off scores or any distinctive profile that can be
used to identify them on an individual basis. The Logical
Memory score determined by discriminant analysis was an
efficient single cut-off score in this sample, but it is too
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close to the population norm to be meaningful in general
clinical use. Other specialized tasks (e.g., measures of reac-
tion time, attention, components of memory encoding0
retrieval) may be needed to characterize these participants
more effectively. Recent studies suggest that cognitive per-
formance is relatively unchanged in chronic Lyme disease
after additional courses of standard antibiotic treatment.
However, given the mild, diffuse nature of their impair-
ments, treatment effects may be most clearly evident as
modest improvement across a battery of tests rather than a
dramatic change in any single task. Future studies that com-
bine cognitive measures with structural or functional imag-
ing will enable us to determine if there are relationships
between specific structural0functional brain abnormalities
and specific types of cognitive impairment. Participants in
this study who met inclusion criteria for its treatment com-
ponent received both MRI and PET scans before and after
treatment, these imaging tools will be used to address some
of these questions.
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